Formaderm by Hecon Biotech Showcases 'Craftsmanship in Aesthetic Medicine' at the 10th National Minimally Invasive Medical Aesthetics Conference

ChongqingApril 3, 2023PR Newswire -- From March 31 to April 2, Maxigen Biotech Inc. (hereinafter referred to as "Maxigen Biotech") showcased its Fumedeng series of products at the "10th National Minimally Invasive Medical Aesthetics Conference of the Chinese Association of Plastics and Aesthetics" held in Chongqing. With a professional approach and advanced product technology, it garnered widespread attention from experts, scholars, institutions, and service providers specializing in medical aesthetics.

Maxigen Biotech's Fumed Series Products: A Professional Interpretation of "Craftsmanship in Creation"

This year marks the 10th anniversary of the "Minimally Invasive Medical Aesthetics Conference." Staying true to its original mission of promoting academic development, this year’s conference upholds the aim of "returning to the essence of medicine" and continues to explore hot topics of public concern. Through diverse formats, it showcases new technologies, concepts, and advancements in the medical aesthetics field. "We are delighted to participate in such a professional-level conference. Not only does it provide us with the opportunity to connect with more experts and scholars in the medical aesthetics field, but it also allows them to better understand Maxigen Biotech's technology and recognize the philosophy behind Maxigen Biotech," said Jiang Yan, China Operations Director of Maxigen Biotech Inc.’s Shanghai branch.

Maxigen Biotech Inc. Showcases Fumei Deng Series Products at the China Minimally Invasive Medical Aesthetics Conference

During the conference, Maxigen Biotech was deeply involved in various sessions, conveying the brand philosophy of "Crafting with Dedication, Presenting Elegance" to attendees through booth displays, seminars, and product presentations. Meanwhile, star products such as Fumei Deng Revitalizing Collagen Peptide Drink and the Fumei Deng series of Sodium Hyaluronate Gel for injection made a striking appearance. Detailed and professional on-site product explanations attracted numerous buyers and visitors, who provided positive feedback on the Fumei Deng series.

Fumei Deng Series Products Gain Wide Attention

As a professional brand under Maxigen Biotech specifically targeting the medical aesthetics field, Fumedé entered the Chinese market in 2016. Relying on the company's over 20 years of technical沉淀 and the resources and academic advantages of the Da Jiang Group, it has developed anti-aging products suitable for Eastern facial features. After years of interdisciplinary research, Maxigen Biotech, in collaboration with the R&D team of Da Jiang Biochemical Technology, successfully created the industry's first collagen tripeptide. Mass spectrometry sequencing analysis revealed that the collagen tripeptide contains nine functional peptides, which, in addition to the collagen protein structure, can also act as key initiators for specific repair functions.

Maxigen Biotech Successfully Creates the Industry's First Collagen Tripeptide

As the smallest tripeptide collagen drink currently on the market, Fumedan Radiance utilizes the internationally patented double emulsion nutrient technology (Double Nutri), with an average particle size of only 1-3 microns, significantly enhancing bioavailability. It also contains high-purity, low-molecular-weight hyaluronic acid for superior hydration and absorption.

In addition,芙媄登utilizes its unique ECHA™ Equilibrium Crosslinking Technology to create sodium hyaluronate gel fillers. This technology unravels hyaluronic acid molecular chains through a special equilibrium device, evenly dispersing minimal doses of micron-level crosslinking agents around, resulting in uniformly crosslinked fillers with excellent viscoelasticity and extrusion force. These provide consumers with a safe, healthy, and long-lasting "age-freezing" experience, gaining popularity and positive feedback since its launch.

Nikki Ni, General Manager of Maxigen Biotech's Shanghai company, stated that Maxigen Biotech has always been highly focused on product research and development as well as manufacturing, committed to creating anti-aging products best suited for Eastern facial features and bone structures, providing consumers with an enhanced experience. During the course of this conference, Maxigen Biotech engaged in frequent interactions with multiple partners and institutions, reaching cooperative intentions, and will further expand its market presence in mainland China. Regarding the future development of Maxigen Biotech and the prospects of collaboration, the partners all expressed high expectations.

Since its establishment in 1998, Maxigen Biotech has been deeply engaged in the research, development, and production of collagen and hyaluronic acid for many years. It has now developed core technology centered on biomacromolecular materials, applied in two major sectors: biomedical materials and medical aesthetics skincare products. Currently, Maxigen Biotech's leading products for medical aesthetic anti-aging include the Fumederm Refining, Plumping, and Lasting series, as well as the Fumederm Collagen Tripeptide Rejuvenating product.

Maxigen Biotech Inc. continues to inherit the cultural heritage of Eastern soft sculpting beauty, with "humanistic aesthetic shaping and scientific aesthetic shaping" as the direction for future ecological aesthetics. In the future, it will continue to focus on the collagen field, fully leverage its technical advantages, and help Chinese consumers achieve natural, harmonious, and healthy Eastern soft sculpting beauty.